Biao Hu
Capital Medical University(CN)Peking University(CN)Society of Nuclear Medicine and Molecular Imaging(US)Beijing Anzhen Hospital(CN)Beijing YouAn Hospital(CN)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Radiopharmaceutical Chemistry and Applications, Cancer Immunotherapy and Biomarkers, Peptidase Inhibition and Analysis, HER2/EGFR in Cancer Research
Most-Cited Works
- → Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy(2020)63 cited
- → HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking(2022)32 cited
- → Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging(2023)31 cited
- → Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT(2022)27 cited
- → IgG-Binding Nanobody Capable of Prolonging Nanobody-Based Radiotracer Plasma Half-Life and Enhancing the Efficacy of Tumor-Targeted Radionuclide Therapy(2022)26 cited
- → Monoclonal-Antibody-Templated Gold Nanoclusters for HER2 Receptors Targeted Fluorescence Imaging(2020)